GET DAILY SIGNALSWhy Is Corbus Pharmaceuticals Holdings (CRBP) Stock Up +3.41% Today?
Key Takeaways
- CRBP shares rose 3.41% to $3.64, adding $0.12 from the prior session's close of $3.52.
- The move came alongside the company's third-quarter 2026 earnings release and corporate update, which highlighted positive clinical data across its oncology and obesity programs.
- Investors focused on encouraging Phase 1b obesity data for CRB-913 and the launch of the Phase 3 TEMPO-1 study for CRB-701, outweighing a wider-than-expected quarterly net loss.
- The stock's move diverged from a reported earnings miss, underscoring that clinical pipeline momentum drove sentiment more than headline financials.
- Traders are watching the upcoming ObesityWeek 2026 presentation, scheduled for November 15, 2026, for additional CRB-913 data.
- For more details on this ticker, explore our Price Targets, Earnings, and Forecast pages.
- Discover how AI-powered trading strategies are navigating this market by exploring Trending AI Robots.
Opening Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage biopharmaceutical company headquartered in Norwood, Massachusetts, focused on developing novel therapies for oncology and obesity. On Tuesday, the stock advanced 3.41% to $3.64, up $0.12 from its prior closing price of $3.52. The move extended a strong prior session and came as the company reported third-quarter 2026 financial results alongside a business update. Markets attributed the advance primarily to encouraging clinical progress across the company's lead programs rather than the reported financial figures.
Q3 Earnings and Corporate Update
The company's earnings release was a mixed picture. CRBP reported a net loss of approximately $37.8 million, or $1.81 per share, for the quarter ended September 30, 2026, a wider loss than the roughly $1.24 per share analysts had expected, with no reported revenue. Operating expenses rose year over year, driven largely by a $15.0 million development milestone recognized under the CSPC licensing agreement for sutantatug envedotin. Notably, the company ended the quarter with $115.3 million in cash, cash equivalents, and investments, which it expects will fund operations into 2028.
Obesity Program Momentum: CRB-913
The strongest catalyst behind the price rally appears tied to the company's CRB-913 program, a once-daily, peripherally restricted CB1 inverse agonist being developed for obesity. In the CANYON-1 Phase 1b study, a 60 mg dose achieved a mean weight loss of 5% after 12 weeks, with no plateau observed at any dose and a favorable safety profile. Based on cross-trial comparisons, the therapy was associated with fewer and milder gastrointestinal adverse events than marketed oral GLP-1 drugs. These results support CRB-913's potential to establish a new class of oral, non-incretin obesity medicines, and full data are set for a late-breaking poster presentation at ObesityWeek 2026 on November 15, 2026.
Oncology Progress: CRB-701
Adding to the bullish narrative, the company's oncology asset, sutantatug envedotin (CRB-701), a next-generation Nectin-4-targeting antibody-drug conjugate, continues to advance. The registrational Phase 3 TEMPO-1 study is now underway in second-line-plus oropharyngeal squamous cell carcinoma, comparing the therapy against investigator's choice of chemotherapy. The company anticipates reporting first-line combination data with Keytruda in the first quarter of 2027, a potential catalyst traders are already monitoring.
Market Context and Trading Activity
The advance in CRBP reflected stock-specific, catalyst-driven momentum rather than broad sector sympathy. As a small-cap, clinical-stage biotech with elevated short interest and a beta well above the market average, the stock tends to exhibit outsized volatility around data readouts and corporate updates. The continued climb following a double-digit gain in the prior session suggests buyers were responding to the forward-looking clinical narrative, even as the quarterly loss came in wider than expected. The stock remains well below its 50-day and 200-day moving averages after a prolonged downtrend, leaving technical resistance levels in focus.
What Comes Next for CRBP
Looking ahead, the most immediate catalyst for CRBP is the ObesityWeek 2026 presentation on November 15, where additional CRB-913 data, including measures such as waist circumference and body mass index, are expected. Further out, investors will watch for first-line CRB-701 combination data anticipated in the first quarter of 2027 and any regulatory feedback from the FDA on the CRB-913 development plan. As a clinical-stage company with no product revenue, execution on trial timelines, capital management, and data quality remain the key risks and uncertainties that could drive future price action in either direction.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot differing by strategy, timeframe, performance metrics, and the symbols it trades. Only the strongest performers are featured in this section, helping traders discover strategies aligned with today's market. Explore the page to see which automated approaches are currently standing out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
CRBP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CRBP turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRBP's RSI Oscillator exited the oversold zone, 38 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +23.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 227 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRBP entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.498). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of drug development services
Industry Biotechnology
Advertisement